Skip to main content
AtriCure, Inc. logo

AtriCure, Inc. — Investor Relations & Filings

Ticker · ATRC ISIN · US04963C2098 LEI · 254900B2I6GPHK2EXM59 US Manufacturing
Filings indexed 1,189 across all filing types
Latest filing 2018-03-02 Director's Dealing
Country US United States of America
Listing US ATRC

About AtriCure, Inc.

https://www.atricure.com

AtriCure, Inc. is a medical device company focused on developing, manufacturing, and selling technologies for the treatment of atrial fibrillation (Afib), management of the left atrial appendage (LAA), and post-operative pain. The company's product portfolio is primarily utilized by cardiothoracic surgeons and electrophysiologists. Key offerings include surgical ablation systems and the AtriClip® LAA Exclusion System, a widely implanted device for LAA management. Additionally, AtriCure provides cryoablation technology, such as the cryoXT™ Probe, which offers a non-opioid approach to pain management following surgical procedures, including amputation.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2018-03-02 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on the grant of performance share awards to executive officers, detailing the terms and recipients of these awards. The key section is Item 5.02, which relates to the departure or appointment of directors or officers and compensatory arrangements. There is no financial statement or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document announces management compensation changes and appointments, fitting the category of Board/Management Information (MANG). The document length is about 4928 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the correct classification is MANG with high confidence.
2018-03-02 English
FORM 4 SUBMISSION
Director's Dealing
2018-03-01 English
10-K
Annual Report FY 2017
2018-02-28 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes an entry into a material definitive agreement (a loan and security agreement), a press release about financial results for the fourth quarter and full year ended December 31, 2017, and a notice of a conference call. The document does not contain the full financial statements or detailed financial analysis itself but references a press release and a conference call. The length is about 5,832 characters, which is relatively short and typical for an 8-K filing. The primary focus is on the announcement of financing activity (loan agreement) and financial results announcement. Given the presence of a new loan agreement and credit facility details, the most appropriate classification is Capital/Financing Update (CAP).
2018-02-26 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated February 20, 2018, for AtriCure, Inc. The key content is under Item 5.02, which reports the departure of two directors from the Board and the appointment of a new Chairman of the Board. This is a clear announcement of changes in the company's board of directors. There is no financial data or detailed report content, just a notification of management changes. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 3493 characters, which is consistent with a typical 8-K filing for management changes, not a full report or earnings release.
2018-02-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.